Elanco Animal Health Incorporated Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Elanco Animal Health Incorporated (ELAN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $1.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-24
- Elanco Animal Health Incorporated effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $1.00M, a 85.71% decline from fiscal 2024.
- Elanco Animal Health Incorporated effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $7.00M, a 63.16% decline from fiscal 2023.
- Elanco Animal Health Incorporated effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was $19.00M.
- Elanco Animal Health Incorporated effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2022 was -$2.00M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $7.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $19.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | -$2.00M 10-K · filed 2025-02-25 | |
| 2021-12-31 | -$8.00M 10-K · filed 2024-02-26 | -$2.00M 10-K · filed 2022-02-28 |
| 2020-12-31 | $23.00M 10-K · filed 2023-03-01 | $17.90M 10-K · filed 2021-03-01 |
| 2019-12-31 | -$4.00M 10-K · filed 2022-02-28 | -$4.20M 10-K · filed 2020-02-28 |
| 2018-12-31 | -$1.00M 10-K · filed 2021-03-01 | $900.00K 10-K · filed 2019-02-20 |
| 2017-12-31 | $800.00K 10-K · filed 2020-02-28 | $1.60M 10-K · filed 2019-02-20 |
| 2016-12-31 | $200.00K 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |